| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The specific molecular targets of Isolugrandoside are not fully characterized. It demonstrates cytotoxicity against the HEp-2 cell line, suggesting interactions with cellular pathways involved in cell survival and proliferation. As a glycoside from Digitalis species, which are known for cardiac glycoside activity, it may have effects on cellular ion transport or signaling pathways. Further studies are needed to identify its primary mechanism of action.
|
|---|---|
| ln Vitro |
In vitro, Isolugrandoside showed higher cytotoxicity against the HEp-2 cell line than other isolated compounds from Digitalis davisiana Heywood. Specific IC50 values are not detailed in the available literature. The compound is a natural product used for studying plant-derived glycosides and exploring novel scaffolds for drug discovery. Further studies are needed to fully characterize its in vitro activity profile.
|
| ln Vivo |
Specific in vivo data for Isolugrandoside are not reported. Given its in vitro cytotoxicity against HEp-2 cells, the compound has potential for in vivo studies in xenograft models of cancer. However, specific published in vivo protocols for this compound are not available. The compound is primarily used as a research tool for natural product chemistry and drug discovery.
|
| Enzyme Assay |
The cytotoxic activity of Isolugrandoside is assessed using standard cell viability assays. HEp-2 cells (human epithelial type 2) are cultured in appropriate media and seeded in 96-well plates. Cells are treated with serial dilutions of the compound for 48-72 hours. Cell viability is measured using MTT, SRB, or CellTiter-Glo assays. IC50 values are calculated from dose-response curves by non-linear regression analysis.
|
| Cell Assay |
For cellular studies, HEp-2 cells are cultured in EMEM or DMEM supplemented with 10% FBS at 37°C in 5% CO₂. Cells are seeded at appropriate densities and treated with Isolugrandoside at concentrations ranging from 0.01 to 100 μM for 48-72 hours. Cell viability is assessed using MTT or SRB assays, and IC50 values are determined from dose-response curves. The compound has a molecular formula of C₂₉H₃₆O₁₆ and a molecular weight of 640.59 g/mol.
|
| Animal Protocol |
In vivo studies for Isolugrandoside would be conducted in appropriate xenograft models using HEp-2 or other sensitive cancer cell lines. Immunodeficient mice would be implanted subcutaneously with cancer cells. Once tumors reach a certain size, the compound would be administered via intraperitoneal injection or oral gavage. Tumor volumes would be measured twice weekly, and body weights monitored for toxicity. However, specific published protocols are not available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Isolugrandoside are not reported. The compound has a molecular formula of C₂₉H₃₆O₁₆ and a molecular weight of 640.59 g/mol. It has a purity of >98% (HPLC). Pharmacokinetic studies would be required to determine parameters such as absorption, distribution, metabolism, and excretion. The compound should be stored as a powder at -20°C for up to 3 years or in solvent at -80°C for up to 1 year.
|
| Toxicity/Toxicokinetics |
Toxicological data for Isolugrandoside are not reported. As a natural product, it is generally considered to have a moderate safety profile. However, comprehensive toxicology studies have not been published. The compound should be handled with appropriate safety precautions in laboratory settings.
|
| References | |
| Additional Infomation |
Reports have indicated that the European ash (Fraxinus ornus) contains isopyranoside, and relevant data is available for reference.
Isolugrandoside is a natural product from Digitalis davisiana with cytotoxicity against HEp-2 cells. Molecular formula: C₂₉H₃₆O₁₆, molecular weight: 640.59. No clinical trials exist. For research use only. |
| Molecular Formula |
C29H36O16
|
|---|---|
| Molecular Weight |
640.586550712585
|
| Exact Mass |
640.2
|
| CAS # |
221660-27-1
|
| PubChem CID |
5318592
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1
|
| Hydrogen Bond Donor Count |
10
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
45
|
| Complexity |
953
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C([C@H]1O[C@@H](OCCC2C=CC(O)=C(O)C=2)[C@H](O)[C@@H](OC(=O)/C=C/C2C=CC(O)=C(O)C=2)[C@@H]1O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O
|
| InChi Key |
JOIWQICOBJLMOP-HPIISDRLSA-N
|
| InChi Code |
InChI=1S/C29H36O16/c30-11-19-22(36)24(38)25(39)28(43-19)42-12-20-23(37)27(45-21(35)6-3-13-1-4-15(31)17(33)9-13)26(40)29(44-20)41-8-7-14-2-5-16(32)18(34)10-14/h1-6,9-10,19-20,22-34,36-40H,7-8,11-12H2/b6-3+/t19-,20-,22-,23-,24+,25-,26-,27+,28-,29-/m1/s1
|
| Chemical Name |
[(2R,3R,4S,5R,6R)-2-[2-(3,4-dihydroxyphenyl)ethoxy]-3,5-dihydroxy-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-4-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5611 mL | 7.8053 mL | 15.6106 mL | |
| 5 mM | 0.3122 mL | 1.5611 mL | 3.1221 mL | |
| 10 mM | 0.1561 mL | 0.7805 mL | 1.5611 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
